🔴 MetaVia is trading 6.7% down today as obesity drug rally cools and profit-taking continues

MetaVia is trading at $1.80, down 6.7% in pre-market, extending a pullback that began after profit-taking on July 14, 2026.

• The stock has experienced significant volatility following optimism surrounding its DA-1726 obesity drug trial milestone.
• Today’s pre-market weakness reflects continued digestion of the recent rally alongside broader market pressure on software and growth sectors.